Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Choosing an index fund for retirement involves comparing Sp500 vs total market exposure, costs, and long-term growth potential.
28,502 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Strategy reports a modest bitcoin purchase from its treasury amid a mid-cap crypto pullback, lifting unrealized losse...
Strategy adds 535 BTC for roughly $43 million, expanding a monumental on-balance-asset position. The total stake now ...
Today’s session showed a rally fade for Plug Power and a broader pullback in hydrogen names. This article breaks down...
Oil prices hold near the high-$80s to low-$90s as the Hormuz disruption tests supply buffers. Market resilience is fu...
When an executive sells stock, investors ask whether it signals trouble or simply personal liquidity needs. This guid...
Discover how Remax RMAX 2025 earnings shape the company’s growth story. We break down revenue drivers, margins, and k...
If SpaceX goes public, investors will chase big headlines and big moves. History suggests year-one volatility is the ...
As Treasury yields rise, SPHD's monthly distributions remain a focal point for income investors. This dividend safety...
Palantir stock has cooled after a run of gains and is trading near its 52-week low. This guide explores what that mea...
In 2026, a wave of renewed focus on critical minerals has many investors watching USA Rare Earth. This guide explains...
Gold had a remarkable run in 2025, with GLD delivering strong gains. This guide explains what happened, what it means...